Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study. Background: Advanced Gastro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results